Immunovia’s vision is to revolutionize blood-based diagnostics and increase survival rates for patients with cancer.
IMMray™ PanCan-d is the first blood-based test dedicated to early detection of pancreatic cancer. It is exclusively available as a laboratory developed test (LDT) from Immunovia, Inc., Marlborough, USA.
About us
Immunovia AB is a diagnostic company with the vision to revolutionize blood-based diagnostics and increase survival rates for patients with cancer. Our first product, IMMray™ PanCan-d is the only blood test currently available specifically for the early detection of pancreatic cancer. The test has unmatched clinical performance. Commercialization of IMMray™ PanCan-d started in August 2021 in the USA and IMMray™ PanCan-d is offered as a laboratory developed test (LDT) exclusively through Immunovia, Inc. For more information see www.immunoviainc.com. Immunovia has initiated since 2016 a prospective clinical validation program for high risk groups for pancreatic cancer involving 30 hospitals and over 10,000 patients from USA and Europe.
Immunovia Interim Report January-March 2022 presentation from April 28th, 2022, with Philipp Mathieu, Acting CEO & President and Karin Almqvist Liwendahl, Chief Financial Officer.
April 2022
Immunovia AB published the company’s Interim Report January-March 2022 on Thursday, April 28, 2022, at 8.00 a.m. CET.
Place: Online event
Place: Hybrid – Online and Møller Institute, University of Cambridge, UK
